Profile data is unavailable for this security.
About the company
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
- Revenue in USD (TTM)1.96bn
- Net income in USD312.32m
- Incorporated2014
- Employees5.80k
- LocationMedpace Holdings Inc5375 Medpace WayCINCINNATI 45227-1543United StatesUSA
- Phone+1 (513) 579-9911
- Fax+1 (302) 655-5049
- Websitehttps://investor.medpace.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Repligen Corp | 607.45m | 14.84m | 8.87bn | 1.78k | 629.03 | 4.50 | 105.04 | 14.61 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Catalent Inc | 4.14bn | -1.18bn | 9.89bn | 17.80k | -- | 2.72 | -- | 2.39 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Exact Sciences Corp | 2.53bn | -240.23m | 9.98bn | 6.50k | -- | 3.17 | -- | 3.94 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 11.21bn | 20.00k | 25.53 | 3.08 | 14.49 | 2.73 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.02bn | 1.31k | 1,595.71 | 12.50 | 204.60 | 8.56 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Medpace Holdings Inc | 1.96bn | 312.32m | 12.10bn | 5.80k | 39.80 | 17.98 | 35.61 | 6.17 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
United Therapeutics Corporation | 2.50bn | 1.05bn | 12.26bn | 1.17k | 13.08 | 2.29 | 11.09 | 4.91 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Viatris Inc | 15.36bn | -56.10m | 12.54bn | 38.00k | -- | 0.6263 | 4.74 | 0.8162 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.67bn | 3.05k | 63.94 | 6.29 | 40.41 | 10.98 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Incyte Corp | 3.77bn | 745.44m | 12.90bn | 2.52k | 17.44 | 2.39 | 15.53 | 3.42 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Natera Inc | 1.21bn | -365.46m | 13.20bn | 3.28k | -- | 16.55 | -- | 10.92 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.14bn | 1.45k | 38.61 | 5.92 | 36.05 | 7.13 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.41bn | 3.40k | 71.84 | 2.84 | 46.37 | 5.83 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.47m | 7.96% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.20m | 7.09% |
Wasatch Advisors, Inc.as of 31 Mar 2024 | 974.42k | 3.15% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 696.96k | 2.25% |
Riverbridge Partners LLCas of 31 Mar 2024 | 606.25k | 1.96% |
TD Asset Management, Inc.as of 31 Mar 2024 | 574.15k | 1.85% |
Geode Capital Management LLCas of 31 Mar 2024 | 532.75k | 1.72% |
Goldman Sachs Asset Management LPas of 31 Mar 2024 | 467.53k | 1.51% |
Invesco Capital Management LLCas of 31 Mar 2024 | 410.01k | 1.32% |
Epoch Investment Partners, Inc.as of 31 Mar 2024 | 406.45k | 1.31% |